Supporting this notion, the Treg population, which included the effector Treg-17 cells, while enhancing IL-17A in Th17 cells initially, was capable of suppressing OPC immunopathology and IBD immunopathology at later time points in our studies ([22], Figure S1b). This evidence concerns the gene IL17A and inflammatory bowel disease.